{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=87",
    "query": {
      "condition": "High-Risk",
      "page": 87
    },
    "page_size": 10
  },
  "pagination": {
    "page": 87,
    "page_size": 10,
    "total_count": 7258,
    "total_pages": 726,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=88&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=86&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T05:13:02.153Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05902988",
      "title": "A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "High Grade Serous Adenocarcinoma of Ovary",
        "Squamous Non-small-cell Lung Cancer",
        "Triple Negative Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Ovarian Carcinosarcoma",
        "Uterine Carcinosarcoma",
        "Uterine Serous Carcinoma",
        "Endometrium Cancer",
        "Chromosomal Instability"
      ],
      "interventions": [
        {
          "name": "VLS-1488",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Volastra Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2023-10-18",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-11-07T05:13:02.153Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05902988"
    },
    {
      "nct_id": "NCT02145403",
      "title": "Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Malignancies",
        "Relapse",
        "Graft-Versus-Host Disease"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 53,
      "start_date": "2014-10",
      "completion_date": "2020-10-16",
      "has_results": true,
      "last_update_posted_date": "2022-01-03",
      "last_synced_at": "2026-11-07T05:13:02.153Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02145403"
    },
    {
      "nct_id": "NCT00278161",
      "title": "Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 94,
      "start_date": "2005-01",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2018-11-05",
      "last_synced_at": "2026-11-07T05:13:02.153Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00278161"
    },
    {
      "nct_id": "NCT01123486",
      "title": "Hydromorphone Pharmacokinetic-Pharmacodynamic Fingerprint",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain",
        "Ventilatory Depression"
      ],
      "interventions": [
        {
          "name": "hydromorphone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "21 Years to 30 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-01",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2015-04-22",
      "last_synced_at": "2026-11-07T05:13:02.153Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01123486"
    },
    {
      "nct_id": "NCT02412670",
      "title": "Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Grade Upper Tract Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Vinblastine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Nephroureterectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2015-08-27",
      "completion_date": "2022-05-10",
      "has_results": true,
      "last_update_posted_date": "2023-07-10",
      "last_synced_at": "2026-11-07T05:13:02.153Z",
      "location_count": 134,
      "location_summary": "Birmingham, Alabama • Aurora, Colorado • Colorado Springs, Colorado + 93 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02412670"
    },
    {
      "nct_id": "NCT03814005",
      "title": "A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Leukemia, Myelomonocytic, Chronic",
        "Leukemia, Myeloid, Acute",
        "Renal Insufficiency",
        "Liver Disease",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Pevonedistat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2019-07-10",
      "completion_date": "2022-04-19",
      "has_results": true,
      "last_update_posted_date": "2024-09-05",
      "last_synced_at": "2026-11-07T05:13:02.153Z",
      "location_count": 2,
      "location_summary": "New York, New York • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03814005"
    },
    {
      "nct_id": "NCT02404194",
      "title": "Targeted Cognitive Training in Clinical High Risk (CHR) for Psychosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Clinical High Risk for Psychosis"
      ],
      "interventions": [
        {
          "name": "Targeted Cognitive Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Computer Games",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "15 Years to 30 Years"
      },
      "enrollment_count": 139,
      "start_date": "2015-03",
      "completion_date": "2021-02-15",
      "has_results": false,
      "last_update_posted_date": "2022-12-02",
      "last_synced_at": "2026-11-07T05:13:02.153Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02404194"
    },
    {
      "nct_id": "NCT04402151",
      "title": "Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Body Radiation Therapy (SBRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "MALE",
        "summary": "21 Years to 90 Years · Male only"
      },
      "enrollment_count": 50,
      "start_date": "2020-06-30",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-11-07T05:13:02.153Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04402151"
    },
    {
      "nct_id": "NCT00186537",
      "title": "Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Insulin Resistance",
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "Fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "Weight Loss",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "30 Years to 65 Years"
      },
      "enrollment_count": 47,
      "start_date": "2003-09",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-11-07T05:13:02.153Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00186537"
    },
    {
      "nct_id": "NCT06794645",
      "title": "Pembrolizumab and Pemetrexed for Progressive Chordoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chordomas",
        "Chordoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed Phase 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Saint John's Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2025-01",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-11-07T05:13:02.153Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06794645"
    }
  ]
}